CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares

Rhea-AI Filing Summary

CareDx, Inc. insider Peter Maag filed a notice to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $328,237.70. The issuer reports 51,734,223 shares outstanding of common stock, listed on NASDAQ. The shares to be sold relate to restricted stock awards dated December 31, 2023 (797 shares) and January 29, 2024 (6,203 shares). The filing also lists recent sales of common stock by Maag between August 4 and August 11, 2026, including transactions of 75,653 shares for $3,576,851.19 and 46,963 shares for $2,178,945.34.

Key Figures

Shares to be sold: 7,000 shares Aggregate market value of planned sale: $328,237.70 Shares outstanding: 51,734,223 shares +4 more

7 metrics

Shares to be sold 7,000 shares Planned sale of common stock through Morgan Stanley Smith Barney LLC

Aggregate market value of planned sale $328,237.70 Value associated with 7,000 shares of common stock

Shares outstanding 51,734,223 shares Common stock outstanding for the issuer

Restricted stock grant 797 shares Restricted stock dated December 31, 2023

Restricted stock grant 6,203 shares Restricted stock dated January 29, 2024

Sale on August 4, 2026 75,653 shares for $3,576,851.19 Common stock sale by Peter Maag

Sale on August 5, 2026 46,963 shares for $2,178,945.34 Common stock sale by Peter Maag

Key Terms

Restricted Stock, Form 144, Executive Financial Services, Common Stock

4 terms

Restricted Stock financial

"Common | 12/31/2023 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

Common Stock financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 04:09 PM Accepted by SEC EDGAR 08/12/2026 - 04:08 PM Learn about SEC filing dates

FAQ

What stock sale is Peter Maag planning according to the Form 144 for CDNA?

Peter Maag plans to sell 7,000 shares of CareDx common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $328,237.70 based on the price information in the filing.

How many CareDx (CDNA) shares are outstanding in this Form 144 filing?

The issuer states that 51,734,223 shares of common stock are outstanding. This figure provides context for the planned sale of 7,000 shares disclosed by insider Peter Maag in the notice.

What recent CareDx (CDNA) stock sales by Peter Maag are disclosed?

The filing lists recent sales including 75,653 shares for $3,576,851.19 on August 4, 2026 and 46,963 shares for $2,178,945.34 on August 5, 2026, along with several additional trades through August 11, 2026.

What is the origin of the 7,000 CareDx (CDNA) shares to be sold?

The 7,000 shares come from restricted stock awards, including 797 shares granted on December 31, 2023 and 6,203 shares granted on January 29, 2024, as identified in the securities-to-be-sold section.

On which exchange is CareDx (CDNA) common stock listed in this filing?

The common stock referenced in the filing is listed on NASDAQ. This listing detail appears in the securities information section describing the planned sale through Morgan Stanley Smith Barney LLC.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7000	328237.70	51734223	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/31/2023	Restricted Stock	Issuer			797	12/31/2023	Not Applicable
Common	01/29/2024	Restricted Stock	Issuer			6203	01/29/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/11/2026	7000	333851.00
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/10/2026	6902	328949.32
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/07/2026	27332	1252491.63
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/05/2026	46963	2178945.34
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/04/2026	75653	3576851.19

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)